Hong Kong firm United Laboratories International Holdings Ltd (HKG: 3933) has announced that its Category 1 drug candidate UBT251 has been tacitly approved in China for a clinical study focusing on non-alcoholic fatty liver disease (NAFLD).
UBT251: A Triple Agonist for Metabolic Improvements
UBT251 is a long-acting GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulin-stimulating peptide)/GCG (glucagon) triple agonist synthesized chemically from peptides. Early human clinical trials of similar products have demonstrated that medication for over 48 weeks effectively reduces blood sugar and weight, decreases liver fat, and improves blood pressure and blood lipids, leading to significant overall metabolic improvements in patients.
United Laboratories’ Milestones and IND Approvals
United Laboratories, the first company in China and the second in the world to have such an agonist cleared for trials, received Investigational New Drug (IND) approvals for UBT251 in type 2 diabetes and weight loss in August and September 2023, respectively. These approvals mark significant milestones in the company’s commitment to advancing treatments for metabolic diseases.-Fineline Info & Tech
